BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing

BRAINSTORM CELL THERAPEUTICS INC.

2026-Q1 EPS reported -$0.19

Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.
Cash, equivalents, and restricted cash $0.2M at March 31, 2026, down from $0.3M at Dec 31, 2025.
R&D expense $0.8M (down from $1.3M); G&A expense $1.3M (down from $1.8M).
Planning Phase 3b ENDURANCE trial of NurOwn for ALS, targeting ~200 patients; BLA submission planned after Part A.
Raised $2M via two private placements in Feb 2026; stockholders' deficit $11M; accounts payable $7.3M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.